High Rate of Copy-Number Alterations in Gastrointestinal and Pancreatic Neuroendocrine Tumors with Unidentified Driver Mutations Abstract #2234

Introduction: The driving genetic alteration leading to neuroendocrine tumor (NET) development has been reported for primary tumors of pancreatic origin, but not for metastases. Moreover, even for primary tumor a significant “dark matter” remains to be explored.
Aim(s): To identify driver genetic alteration in gastroenteropancreatic NET (GEP-NET) metastases.
Materials and methods: A hybrid capture sequencing of 500 tumor suppressor genes and oncogenes was performed. Patients’ tumor DNA were sequenced and compared with germline DNA. Copy-number (CN) variant analysis was performed based on the sequencing data.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Amit Tirosh

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2196 The Neuroendocrine Phenotype, Genomic Profile, and Therapeutic Sensitivity of GEPNET Cell Lines
Introduction: Patient tumour-derived cell lines have been widely used for studying the molecular mechanisms of tumours and their response to therapy. The establishment of cell lines from gastro-entero-pancreatic neuroendocrine tumours (GEPNETs) has proved difficult, but despite the challenges a limited amount of cell lines now exists.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Tobias Hofving
#1282 Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Frequency, Treatment and Prognosis
Introduction: Data on peritoneal metastases (PM) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are scarce.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Ariana Madani
#1521 Metastatic Disease in Gastroenteropancreatic Neuroendocrine Cancer: Incidence, Treatment and Survival
Introduction: Data on patients with metastatic disease from GEP-NETs are rare.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Ariana Madani
#563 Role of Ga-68 Somatostatin Receptor PET/CT in the Assessment of Response to Radiofrequency Ablation in Hepatic Metastases of Neuroendocrine Tumors
Introduction: Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) present frequently with hepatic metastases. Radiofrequency ablation (RFA) is an important local ablative treatment for hepatic metastases.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum
#1059 Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era
Introduction: We have conducted molecular profiling through high-throughput molecular test as part of clinical practice for patients with advanced gastrointestinal (GI) cancer, or rare cancer including gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Seung Kim
Authors: Kim S, Yoo K, Jung K, Lee S, ...